Rhizen Pharmaceuticals has begun a first-in-human Phase I study of RP6530, a dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, for the treatment of patients with advanced hematological malignancies. The study is designed primarily to establish the safety and tolerability of RP6530. Secondary objectives include clinical efficacy assessment and biomarker response to allow dose determination and potential patient stratification in subsequent expansion studies. The study will be conducted at San Raffael Institute, Milan, Italy with Dr. Andres Ferrari as the Principal Investigator.

RP6530 is the second lead from Rhizen’s robust pipeline that comprises of small molecules targeting cancer, immuno-inflammation, and metabolic diseases, to enter clinical development. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of the tumor microenvironment at clinically achievable concentrations.